SCHEMBL5536862

SCHEMBL5536862

Cc1ccc(O)c2c1OCC2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 5/20 0.54
MAOB P27338 3/20 0.54
ESR1 P03372 2/20 0.37
ESR2 Q92731 2/20 0.37
DRD1 P21728 4/20 0.34
DRD2 P14416 2/20 0.34
HTR2A P28223 2/20 0.34
DRD3 P35462 2/20 0.34
DRD4 P21917 1/20 0.34
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
GLA P06280 1/20 0.33
GAA P10253 1/20 0.33
HPGD P15428 1/20 0.33
MAPK1 P28482 1/20 0.33
CASP1 P29466 1/20 0.33
CASP7 P55210 1/20 0.33
HSD17B10 Q99714 1/20 0.33
BCL2L1 Q07817 1/20 0.31
BAD Q92934 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5545770 0.84 MAOA (0.59) MAOAMAOBESR1ESR2DRD1
SCHEMBL6127893 0.83 MAOA (0.47) MAOAMAOBHTR2AALDH1A1
SCHEMBL19834678 0.80 MAOA (0.42) MAOAMAOBESR1ESR2DRD1
SCHEMBL11358607 0.77 DRD2 (0.49) MAOAMAOBESR1ESR2DRD1
SCHEMBL24819189 0.76 MAPT (0.39) MAOAMAOBHTR2AALDH1A1CASP1
SCHEMBL20127248 0.76 MAOA (0.39) MAOAMAOBHTR2AALDH1A1
SCHEMBL5536859 0.76 MAOA (0.42) MAOAMAOBALDH1A1
SCHEMBL20127247 0.74 MAOA (0.41) MAOAMAOBKDM4EALDH1A1HPGD
SCHEMBL8737441 0.73 MAOA (0.37) MAOAMAOBHTR2A
SCHEMBL19978377 0.73 MAOA (0.37) MAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAOA 2885/4885MAOB 2140/4885ESR1 1578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.